---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000044"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:49:58.140925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q3 revenue up 22%, raises 2025 guidance, CFO transition announced

## Summary
- Q3 2025 revenue $354M (+22% YoY); royalty revenue $236M (+52% YoY); GAAP diluted EPS $1.43 (+36% YoY); non-GAAP diluted EPS $1.72 (+35% YoY).
- Raises full-year 2025 guidance: total revenue $1,300-$1,375M, royalty $850-$880M, Adj. EBITDA $885-$935M, non-GAAP EPS $6.10-$6.50.
- Agreed to acquire Elektrofi for $750M up-front plus up to $150M in milestones; expected close Q4 2025.
- CFO Nicole LaBrosse to depart by March 30, 2026 or when successor hired; external search underway; departure not due to disagreement.
- Two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe; VYVDURA prefilled syringe in Japan.

## SEC filing metadata
- accession: 0001159036-25-000044
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/0001159036-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000044/halo-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000044
- JSON: https://secwatch.observer/filing/0001159036-25-000044.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.